Navigation Links
An Alzheimer's vaccine?
Date:11/12/2007

Could a new vaccine be the key to stopping Alzheimers disease" A new research study from the Oklahoma Medical Research Foundation (OMRF) shows that immunization could offer a way to blunt or even prevent the deadly, memory-robbing disease.

OMRF scientists immunized Alzheimers mice with a protein believed to play a key role in the disease-causing process. The mice who received the vaccination showed a significant reduction in the build-up of protein plaques that, when present in the brain for long periods of time, are believed to cause the cell death, memory loss and neurological dysfunction characteristic of Alzheimers.

The immunized mice also showed better cognitive performance than control mice had not received the vaccine.

These results are extremely exciting, said Jordan Tang, Ph.D., the OMRF researcher who led the study. They certainly show that this vaccination approach warrants additional investigation as a therapy for Alzheimers disease.

The new research appears in The Journal of the Federation of American Societies for Experimental Biology.

Tang and his colleagues at OMRF previously had identified the cutting enzyme (known as memapsin 2) that creates the protein fragments believed to be the culprit behind Alzheimers. In the current study, researchers used mice that had been genetically engineered to develop symptoms of Alzheimers, then immunized the animals with memapsin 2.

What we saw is that the mice immunized with memapsin 2 developed 35 percent fewer plaques than their non-vaccinated counterparts, said Tang. Those immunized mice also performed better than control mice in tests designed to assess their cognitive function.

Tangs work with memapsin 2 also has led to the creation of an experimental drug to treat Alzheimers disease. That drug, which works by inhibiting the cutting enzyme, began human clinical trials in the summer of 2007.

Tang emphasized that the vaccine approach should be viewed as a supplement torather than substitute forthe experimental inhibitor and other treatments currently in development for the illness.

Alzheimers is a complicated, multi-faceted disease, said the OMRF researcher. As with illnesses like cancer and heart disease, Alzheimers demands that we develop many different approaches to combat it. We cannot rely on a one-size-fits-all strategy, because what works in one patient will not necessarily have in another.

A vaccination approachgetting the immune system to clean up the plaqueshas been considered a promising way to tackle the disease, but its success has been limited. In 2002, for example, the pharmaceutical company Elan halted trials of a different vaccine after 15 patients suffered swelling of the central nervous system.

OMRF President Stephen Prescott, M.D., is hopeful that Tangs work will avoid the pitfalls that beset Elans vaccine. This vaccination stimulates the immune system more gently than previous Alzheimers vaccines, so we are optimistic about its prospects going forward, he said. Once again, Dr. Tang has found an innovative way to make inroads against a devastating and poorly understood disease.

The next step, said Tang, will be to progress the work to the point that it can be tested in humans. There currently is no effective treatment for Alzheimers disease, so we must explore every possible option to find a way to stop it, he said.

The research was supported, in part, by a grant from the Alzheimers Association.

The Alzheimers Association is pleased to provide funding for innovative work such as this to develop possible new therapies for Alzheimer's, said William Thies, Ph.D., vice president for Medical & Scientific Relations at the Alzheimers Association. It is important to encourage imaginative researchers to test unconventional strategies, as Dr. Tang has done here. We face an overwhelming epidemic of Alzheimer's and dementia if we don't change the current unsatisfactory situation by greatly improving early detection, treatment and prevention.


'/>"/>

Contact: Adam Cohen
adam-cohen@omrf.org
405-271-7159
Oklahoma Medical Research Foundation
Source:Eurekalert

Related biology news :

1. Paradigm shift in Alzheimerss research: new treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... About Voice Recognition Biometrics Voice recognition biometrics ... a stored voiceprint template. Acoustic features of an ... are compared to distinguish between individual voices. Voice ... PCs already have a microphone and can authenticate ... are most likely to be deployed in telephone-based ...
(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
(Date:2/3/2017)... 3, 2017 A new independent identity strategy ... LLP (IdSP) . Designed to fill a critical niche ... market, founding partners Mark Crego and ... just in identity expertise that span federal governments, the ... The Crego-Kephart combined expertise has a common theme born ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... 2017 The Biotech industry is today,s ... following equities: ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ), ... Inc. (NASDAQ: ARNA ), and Marinus Pharmaceuticals Inc. ... Healthcare sector, which was narrowly mixed on Monday, February 27 ... less than 0.1%, while shares of health care companies in ...
(Date:2/27/2017)... February 27, 2017 Four US ... evaluation today, and they are: Anthera Pharmaceuticals Inc. (NASDAQ: ... California Inc. (NASDAQ: PACB), and Conatus Pharmaceuticals Inc. (NASDAQ: ... ETF Trends, market observers are growing more bullish on ... enact reforms to free cash held overseas for tax ...
(Date:2/26/2017)... ... February 26, 2017 , ... Rob Lowe is a well recognized television ... called "Informed," focuses on issues that are important to the American public and important ... which has been a hot topic around the world for a few years. , ...
(Date:2/24/2017)... KNOXVILLE, Tenn. , Feb. 24, 2017 /PRNewswire/ ... ) ("Provectus" or the "Company"), a clinical-stage oncology ... information regarding the deadline to participate in its ... million units, consisting of shares of common stock ... stockholders and holders of listed warrants. ...
Breaking Biology Technology: